Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Eligibility Criteria

• * Age: ≤ 60 years of age
• * Performance Status: Karnofsky ≥ 70%, Lansky play score ≥ 70
• * Consent: Voluntary written consent (adult or legally authorized representative; or parental/guardian)
• * Adequate Organ Function:
• * Renal: Creatinine \<2x upper limit of normal. Patients above this limit must have creatinine clearance ≥ 40 ml/min/1.73m2 as determined by an age-appropriate method, such as cystatin C GFR.
• * Hepatic: Bilirubin, AST, alkaline phosphatase \<4 times the upper limit of institutional normal
• * Pulmonary: Diffusion capacity of oxygen, corrected for hemoglobin, \> 50% of predicted. For pediatric patients not able to undergo PFTs or diffusion testing: O2 sat of \>95% on room air
• * Cardiac: Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction \> 45%. For children not able to cooperate with MUGA or echocardiography, such should be clearly stated in the physician's documentation
• * HIV Status: HIV infection with undetectable viral load. All HIV+ patients must be evaluated by Infectious Disease (ID) and a HIV management plan establish prior to transplantation
• * Chemotherapy refractory large cell and high grade NHL (i.e., progressive disease after \> 2 salvage regimens)
• * CML in blast crisis
• * Large cell lymphoma, mantle cell lymphoma and Hodgkin disease that is progressing on salvage therapy.
• * Evidence of progressive disease by imaging modalities or biopsy - persistent PET activity, though possibly related to lymphoma, is not an exclusion criterion in the absence of CT changes indicating progression.
• * Active central nervous system malignancy
• * if ≤ 18 years old, prior myeloablative transplant within the last 6 months. If \>18 years old prior myeloablative allotransplant or autologous transplant
• * Active HIV infection or known HIV positive serology
• * active uncontrolled infection
• * Pregnant or breastfeeding. The agents used in this study include Pregnancy Category D: known to cause harm to a fetus. Females of childbearing potential must have a negative pregnancy test prior to starting therapy.